A monoclonal antibody against synthetic Aβ dimer assemblies neutralizes brain-derived synaptic plasticity-disrupting Aβ

Journal of Neurochemistry

Volumn 119, Issue 1, 2011, Pages 189-201

  O'Nuallain, Brian ^a   Klyubin, Igor ^b   Mc Donald, Jessica M ^a   Foster, James S ^c   Welzel, Alfred ^a   Barry, Andrew ^b   Dykoski, Richard K ^d   Cleary, James P ^d   Gebbink, Martijn F B G ^e   Rowan, Michael J ^b   Walsh, Dominic M ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b TRINITY COLLEGE DUBLIN   (Ireland)

^c UNIVERSITY OF TENNESSEE GRADUATE SCHOOL OF MEDICINE   (United States)

^d VA MEDICAL CENTER   (United States)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Aggregates; Alzheimer's disease; amyloid; Immunotherapy; Long term; potentiation; Protofibrils

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN DIMER; AMYLOID PRECURSOR PROTEIN; ANTIGEN; DIMER; DODECYL SULFATE SODIUM; IMMUNOGLOBULIN M; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 3C6; MONOCLONAL ANTIBODY 4B5; MONOMER; TOXIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG TARGETING; MALE; NERVE CELL PLASTICITY; NEUROTOXICITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN BINDING; RAT;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ANTIBODIES, MONOCLONAL; BLOTTING, WESTERN; BRAIN CHEMISTRY; CROSS-LINKING REAGENTS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ELECTROPHYSIOLOGICAL PHENOMENA; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOGLOBULIN M; IMMUNOPRECIPITATION; LONG-TERM POTENTIATION; MICE; NEURONAL PLASTICITY; PROTEIN BINDING; SYNAPSES; TISSUE EXTRACTS;

EID: 84860389711     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2011.07389.x     Document Type: Article

References (75)

1. Adekar S. P., Klyubin I., Macy S., Rowan M. J., Solomon A., Dessain S. K., and, O'Nuallain B., (2010) Inherent anti-amyloidogenic activity of human immunoglobulin gamma heavy chains. J. Biol. Chem. 285, 1066-1074.
2. Alzheimer A., (1906) Über einen eigenartigen schweren Erkrankungsproze! der Hirnrinde. Neurologisches Centralblatt 23, 1129-1136.
3. Arancio O., and, Chao M. V., (2007) Neurotrophins, synaptic plasticity and dementia. Curr. Opin. Neurobiol. 17, 325-330. (Pubitemid 46880319)
4. Banks W. A., Farr S. A., Morley J. E., Wolf K. M., Geylis V., and, Steinitz M., (2007) Anti-amyloid beta protein antibody passage across the blood-brain barrier in the SAMP8 mouse model of Alzheimer's disease: an age-related selective uptake with reversal of learning impairment. Exp. Neurol. 206, 248-256. (Pubitemid 47094769)
5. Barghorn S., Nimmrich V., Striebinger A., et al. (2005) Globular amyloid beta-peptide oligomer-a homogenous and stable neuropathological protein in Alzheimer's disease. J. Neurochem. 95, 834-847. (Pubitemid 41567174)
6. Barlow D. J., Edwards M. S., and, Thornton J. M., (1986) Continuous and discontinuous protein antigenic determinants. Nature 322, 747-748. (Pubitemid 16074126)
7. Biere A. L., Ostaszewski B., Stimson E. R., Hyman B. T., Maggio J. E., and, Selkoe D. J., (1996) Amyloid beta-peptide is transported on lipoproteins and albumin in human plasma. J. Biol. Chem. 271, 32916-32922. (Pubitemid 27008725)
8. Carmeliet P., Schoonjans L., Kieckens L., Ream B., Degen J., Bronson R., De Vos. R., van den Oord J. J., Collen D., and, Mulligan R. C., (1994) Physiological consequences of loss of plasminogen activator gene function in mice. Nature 368, 419-424. (Pubitemid 24115347)
9. Cleary J. P., Walsh D. M., Hofmeister J. J., Shankar G. M., Kuskowski M. A., Selkoe D. J., and, Ashe K. H., (2005) Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat. Neurosci. 8, 79-84. (Pubitemid 41236735)
10. Davies L., Wolska B., Hilbich C., Multhaup G., Martins R., Simms G., Beyreuther K., and, Masters C. L., (1988) A4 amyloid protein deposition and the diagnosis of Alzheimer's disease: prevalence in aged brains determined by immunocytochemistry compared with conventional neuropathologic techniques. Neurology 38, 1688-1693. (Pubitemid 18265030)
11. Englund H., Sehlin D., Johansson A. S., Nilsson L. N., Gellerfors P., Paulie S., Lannfelt L., and, Pettersson F. E., (2007) Sensitive ELISA detection of amyloid-beta protofibrils in biological samples. J. Neurochem. 103, 334-345. (Pubitemid 47404222)
12. Ferri C. P., Prince M., Brayne C., et al. (2005) Global prevalence of dementia: a Delphi consensus study. Lancet 366, 2112-2117. (Pubitemid 41797645)
13. Freir D. B., Nicoll A. J., Klyubin I., et al. (2011) Interaction between prion protein and toxic amyloid beta assemblies can be therapeutically targeted at multiple sites. Nat. Commun. 2, 336.
14. Games D., Buttini M., Kobayashi D., Schenk D., and, Seubert P., (2006) Mice as models: transgenic approaches and Alzheimer's disease. J. Alzheimers Dis. 9, 133-149. (Pubitemid 44255487)
15. Gandy S., (2010) Testing the amyloid hypothesis of Alzheimer's disease in vivo. Lancet Neurol. 9, 333-335.
16. Giacomelli C. E., and, Norde W., (2005) Conformational changes of the amyloid beta-peptide (1-40) adsorbed on solid surfaces. Macromol. Biosci. 5, 401-407. (Pubitemid 40813976)
17. Gilman S., Koller M., Black R. S., et al. (2005) Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64, 1553-1562. (Pubitemid 40617691)
18. Goldsteins G., Persson H., Andersson K., Olofsson A., Dacklin I., Edvinsson A., Saraiva M. J., and, Lundgren E., (1999) Exposure of cryptic epitopes on transthyretin only in amyloid and in amyloidogenic mutants. Proc. Natl. Acad. Sci. USA 96, 3108-3113. (Pubitemid 29148852)
19. Hardy J., and, Allsop D., (1991) Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol. Sci. 12, 383-388.
20. Hillen H., Barghorn S., Striebinger A., et al. (2010) Generation and therapeutic efficacy of highly oligomer-specific beta-amyloid antibodies. J. Neurosci. 30, 10369-10379.
21. Hu N. W., Smith I. M., Walsh D. M, and, Rowan M. J., (2008) Soluble amyloid-beta peptides potently disrupt hippocampal synaptic plasticity in the absence of cerebrovascular dysfuntion in vivo. Brain 131, 2414-2424.
22. Jensen M., Hartmann T., Engvall B., et al. (2000) Quantification of Alzheimer amyloid beta peptides ending at residues 40 and 42 by novel ELISA systems. Mol. Med. 6, 291-302.
23. Johnson-Wood K., Lee M., Motter R., et al. (1997) Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease. Proc. Natl. Acad. Sci. USA 94, 1550-1555.
24. Kayed R., Head E., Thompson J. L., McIntire T. M., Milton S. C., Cotman C. W., and, Glabe C. G., (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300, 486-489. (Pubitemid 36444329)
25. Khachaturian Z. S., (1985) Diagnosis of Alzheimer's disease. Arch. Neurol. 42, 1097-1105. (Pubitemid 16236926)
26. Kidd M., (1964) Alzheimer's disease-an electron microscopical study. Brain 87, 307-320.
27. Klyubin I., Betts V., Welzel A. T., et al. (2008) Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization. J. Neurosci. 28, 4231-4237.
28. Kohler G., and, Milstein C., (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256, 495-497.
29. Kok W. M., Scanlon D. B., Karas J. A., Miles L. A., Tew D. J., Parker M. W., Barnham K. J., and, Hutton C. A., (2009) Solid-phase synthesis of homodimeric peptides: preparation of covalently-linked dimers of amyloid beta peptide. Chem. Commun (Camb) 41, 6228-6230.
30. Korth C., Stierli B., Streit P., et al. (1997) Prion (PrPSc)-specific epitope defined by a monoclonal antibody. Nature 390, 74-77. (Pubitemid 27494758)
31. Kranenburg O., Bouma B., Kroon-Batenburg L. M., Reijerkerk A., Wu Y. P., Voest E. E., and, Gebbink M. F., (2002) Tissue-type plasminogen activator is a multiligand cross-beta structure receptor. Curr. Biol. 12, 1833-1839. (Pubitemid 35273903)
32. Kuo Y. M., Emmerling M. R., Vigo-Pelfrey C., Kasunic T. C., Kirkpatrick J. B., Murdoch G. H., Ball M. J., and, Roher A. E., (1996) Water-soluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains. J. Biol. Chem. 271, 4077-4081.
33. Lacor P. N., Buniel M. C., Furlow P. W., Clemente A. S., Velasco P. T., Wood M., Viola K. L., and, Klein W. L., (2007) Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J. Neurosci. 27, 796-807. (Pubitemid 46174498)
34. Lafaye P., Achour I., England P., Duyckaerts C., and, Rougeon F., (2009) Single-domain antibodies recognize selectively small oligomeric forms of amyloid beta, prevent Abeta-induced neurotoxicity and inhibit fibril formation. Mol. Immunol. 46, 695-704.
35. Lambert M. P., Barlow A. K., Chromy B. A., et al. (1998) Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. USA 95, 6448-6453.
36. Lambert M. P., Viola K. L., Chromy B. A., Chang L., Morgan T. E., Yu J., Venton D. L., Krafft G. A., Finch C. E., and, Klein W. L., (2001) Vaccination with soluble Abeta oligomers generates toxicity-neutralizing antibodies. J. Neurochem. 79, 595-605. (Pubitemid 33029933)
37. Lambert M. P., Velasco P. T., Chang L., et al. (2007) Monoclonal antibodies that target pathological assemblies of Abeta. J. Neurochem. 100, 23-35. (Pubitemid 46085837)
38. Lee E. B., Leng L. Z., Zhang B., Kwong L., Trojanowski J. Q., Abel T., and, Lee V. M., (2006) Targeting amyloid-beta peptide (Abeta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) transgenic mice. J. Biol. Chem. 281, 4292-4299. (Pubitemid 43847859)
39. Lesne S., Koh M. T., Kotilinek L., Kayed R., Glabe C. G., Yang A., Gallagher M., and, Ashe K. H., (2006) A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440, 352-357.
40. Linke R. P., Zucker-Franklin D., and, Franklin E. D., (1973) Morphologic, chemical, and immunologic studies of amyloid-like fibrils formed from Bence Jones Proteins by proteolysis. J. Immunol. 111, 10-23.
41. Martins I. C., Kuperstein I., Wilkinson H., et al. (2008) Lipids revert inert Abeta amyloid fibrils to neurotoxic protofibrils that affect learning in mice. EMBO J. 27, 224-233.
42. Mc Donald J. M., Savva G. M., Brayne C., Welzel A. T., Forster G., Shankar G. M., Selkoe D. J., Ince P. G., and, Walsh D. M., (2010) The presence of sodium dodecyl sulphate-stable Abeta dimers is strongly associated with Alzheimer-type dementia. Brain 133, 1328-1341.
43. Melchor J. P., Pawlak R., and, Strickland S., (2003) The tissue plasminogen activator-plasminogen proteolytic cascade accelerates amyloid-beta (Abeta) degradation and inhibits Abeta-induced neurodegeneration. J. Neurosci. 23, 8867-8871. (Pubitemid 37210899)
44. Noguchi A., Matsumara S., Dezawa M., et al. (2009) Isolation and characterization of patient-derived, toxic, high mass amyloid beta-protein (Abeta) assembly from Alzheimer disease brains. J. Biol. Chem. 284, 32895-32905.
45. Notkins A. L., (2004) Polyreactivity of antibody molecules. Trends Immunol. 25, 174-179. (Pubitemid 38368164)
46. O'Nuallain B., and, Wetzel R., (2002) Conformational Abs recognizing a generic amyloid fibril epitope. Proc. Natl. Acad. Sci. USA 99, 1485-1490. (Pubitemid 34136519)
47. O'Nuallain B., Hrncic R., Wall J. S., Weiss D. T., and, Solomon A., (2006) Diagnostic and therapeutic potential of amyloid-reactive IgG antibodies contained in human sera. J. Immunol. 176, 7071-7078. (Pubitemid 43787888)
48. O'Nuallain B., Allen A., Ataman D., Weiss D. T., Solomon A., and, Wall J. S., (2007) Phage display and peptide mapping of an immunoglobulin light chain fibril-related conformational epitope. Biochemistry 46, 13049-13058. (Pubitemid 350086223)
49. O'Nuallain B., Acero L., Williams A. D., Koeppen H. P., Weber A., Schwarz H. P., Wall J. S., Weiss D. T., and, Solomon A., (2008) Human plasma contains cross-reactive Abeta conformer-specific IgG antibodies. Biochemistry 47, 12254-12256.
50. O'Nuallain B., Freir D. B., Nicoll A. J., Risse E., Ferguson N., Herron C. E., Collinge J., and, Walsh D. M., (2010) Amyloid beta-protein dimers rapidly form stable synaptotoxic protofibrils. J. Neurosci. 30, 14411-14419.
51. Puzzo D., Privitera L., Leznik E., Fa M., Staniszewski A., Palmeri A., and, Arancio O., (2008) Picomolar amyloid-beta positively modulates synaptic plasticity and memory in hippocampus. J. Neurosci. 28, 14537-14545.
52. Querfurth H. W., and, LaFerla F. M., (2010) Alzheimer's disease. N. Engl. J. Med. 362, 329-344.
53. Roher A. E., Chaney M. O., Kuo Y. M., et al. (1996) Morphology and toxicity of Abeta-(1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's disease. J. Biol. Chem. 271, 20631-20635. (Pubitemid 26281842)
54. Sandberg A., Luheshi L. M., Sollvander S., et al. (2010) Stabilization of neurotoxic Alzheimer amyloid-{beta} oligomers by protein engineering. Proc. Natl. Acad. Sci. USA 107, 15595-15600.
55. Schagger H., and, von Jagow G., (1987) Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa. Anal. Biochem. 166, 368-379. (Pubitemid 18004907)
56. Schenk D., (2002) Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning. Nat. Rev. Neurosci. 3, 824-828. (Pubitemid 135706694)
57. Selkoe D. J., (1991) The molecular pathology of Alzheimer's disease. Neuron 6, 487-498.
58. Selkoe D. J., (2001) Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 81, 741-766. (Pubitemid 32267077)
59. Seubert P., Vigo-Pelfrey C., Esch F., et al. (1992) Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature 359, 325-327.
60. Shankar G. M., and, Walsh D. M., (2009) Alzheimer's disease: synaptic dysfunction and Abeta. Mol. Neurodegener. 4, 48.
61. Shankar G. M., Li S. M., Mehta T. H., et al. (2008) Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 14, 837-842.
62. Shankar G. M., Welzel A. T., McDonald J. M., Selkoe D. J., and, Walsh D. M., (2011) Isolation of low-n amyloid beta-protein oligomers from cultured cells, CSF, and brain. Methods Mol. Biol. 670, 33-44.
63. Shevchenko A., Wilm M., Vorm O., and, Mann M., (1996) Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal. Chem. 68, 850-858.
64. Solomon B., Koppel R., Hanan E., and, Katzav T., (1996) Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide. Proc. Natl. Acad. Sci. USA 93, 452-455. (Pubitemid 26038175)
65. Stefani M., (2004) Protein misfolding and aggregation: new examples in medicine and biology of the dark side of the protein world. Biochim. Biophys. Acta 1739, 5-25. (Pubitemid 39647706)
66. Vigo-Pelfrey C., Lee D., Keim P., Lieberburg I., and, Schenk D. B., (1993) Characterization of beta-amyloid peptide from human cerebrospinal fluid. J. Neurochem. 61, 1965-1968. (Pubitemid 23317227)
67. Villemagne V. L., Perez K. A., Pike K. E., et al. (2010) Blood-borne amyloid-beta dimer correlates with clinical markers of Alzheimer's disease. J. Neurosci. 30, 6315-6322.
68. Vollmers H. P., Wozniak E., Stepien-Botsch E., Zimmermann U., and, Muller-Hermelink H. K., (1996) A rapid method for purification of monoclonal human IgM from mass culture. Hum. Antibodies Hybridomas 7, 37-41.
69. Wall J., Schell M., Murphy C., Hrncic R., Stevens F. J., and, Solomon A., (1999) Thermodynamic instability of human lambda 6 light chains: correlation with fibrillogenicity. Biochemistry 38, 14101-14108. (Pubitemid 29504243)
70. Walsh D. M., and, Selkoe D. J., (2007) A beta oligomers-a decade of discovery. J. Neurochem. 101, 1172-1184.
71. Walsh D. M., Lomakin A., Benedek G. B., Condron M. M., and, Teplow D. B., (1997) Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate. J. Biol. Chem. 272, 22364-22372. (Pubitemid 27382873)
72. Walsh D. M., Hartley D. M., Kusumoto Y., Fezoui Y., Condron M. M., Lomakin A., Benedek G. B., Selkoe D. J., and, Teplow D. B., (1999) Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. J. Biol. Chem. 274, 25945-25952.
73. Walsh D. M., Klyubin I., Fadeeva J. V., Cullen W. K., Anwyl R., Wolfe M. S., Rowan M. J., and, Selkoe D. J., (2002) Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535-539. (Pubitemid 34288854)
74. Westermark P., Benson M. D., Buxbaum J. N., Cohen A. S., Frangione B., Ikeda S., Masters C. L., Merlini G., Saraiva M. J., and, Sipe J. D., (2005) Amyloid: toward terminology clarification. Report from the Nomenclature Committee of the International Society of Amyloidosis. Amyloid 12, 1-4. (Pubitemid 40896938)
75. Yokoyama W. M., Christensen M., Dos Santos G., and, Miller D., (2006) Production of Monoclonal Antibodies. Current Protocols in Immunology 74, 2.5.1-2.5.25.